John Kamerud

1.9k total citations
17 papers, 927 citations indexed

About

John Kamerud is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, John Kamerud has authored 17 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Radiology, Nuclear Medicine and Imaging, 11 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in John Kamerud's work include Biosimilars and Bioanalytical Methods (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Advanced Biosensing Techniques and Applications (4 papers). John Kamerud is often cited by papers focused on Biosimilars and Bioanalytical Methods (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Advanced Biosensing Techniques and Applications (4 papers). John Kamerud collaborates with scholars based in United States, Switzerland and Sweden. John Kamerud's co-authors include Joseph L. Napoli, B W Hollis, J Lorenz, Ago Ahene, Lindsay E. King, Marian Kelley, Jihong Yang, Bruce W. Hollis, Jean‐François Beaulieu and Hossein Salimi-Moosavi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Bacteriology and Clinical Chemistry.

In The Last Decade

John Kamerud

16 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Kamerud United States 9 379 339 238 197 139 17 927
Simone D. Holligan Canada 9 144 0.4× 94 0.3× 152 0.6× 102 0.5× 39 0.3× 19 809
Rakesh R. Misra United States 12 74 0.2× 287 0.8× 47 0.2× 34 0.2× 124 0.9× 18 1.0k
Sanhong Yu United States 14 462 1.2× 155 0.5× 510 2.1× 21 0.1× 188 1.4× 21 1.2k
Tobias Weissenbacher Germany 16 167 0.4× 165 0.5× 161 0.7× 51 0.3× 25 0.2× 40 717
Marcel J.W. Janssen Netherlands 12 109 0.3× 203 0.6× 39 0.2× 19 0.1× 59 0.4× 25 621
Louise Hansen Denmark 13 118 0.3× 158 0.5× 55 0.2× 43 0.2× 73 0.5× 17 592
Jérôme Guechot France 21 47 0.1× 228 0.7× 74 0.3× 163 0.8× 34 0.2× 49 1.5k
Marco Ceroti Italy 17 83 0.2× 98 0.3× 207 0.9× 67 0.3× 155 1.1× 28 1.1k
Şükrü Palanduz Türkiye 18 54 0.1× 400 1.2× 78 0.3× 37 0.2× 41 0.3× 90 1.0k
Lieying Fan China 20 93 0.2× 352 1.0× 138 0.6× 43 0.2× 23 0.2× 63 1.2k

Countries citing papers authored by John Kamerud

Since Specialization
Citations

This map shows the geographic impact of John Kamerud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Kamerud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Kamerud more than expected).

Fields of papers citing papers by John Kamerud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Kamerud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Kamerud. The network helps show where John Kamerud may publish in the future.

Co-authorship network of co-authors of John Kamerud

This figure shows the co-authorship network connecting the top 25 collaborators of John Kamerud. A scholar is included among the top collaborators of John Kamerud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Kamerud. John Kamerud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Yang, Tong‐Yuan, Manuela Braun, Fraser McBlane, et al.. (2022). Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Molecular Therapy — Methods & Clinical Development. 26. 471–494. 48 indexed citations
2.
3.
4.
Tan, Charles Y., et al.. (2020). Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population. The AAPS Journal. 22(2). 19–19. 4 indexed citations
5.
6.
Gorovits, Boris, et al.. (2019). Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis. The AAPS Journal. 21(5). 76–76. 2 indexed citations
7.
Gorovits, Boris, et al.. (2019). Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points. The AAPS Journal. 21(4). 71–71. 4 indexed citations
8.
9.
10.
11.
Kelley, Marian, Ago Ahene, Boris Gorovits, et al.. (2013). Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation. The AAPS Journal. 15(3). 646–658. 47 indexed citations
12.
13.
Benecky, Michael J., et al.. (1998). Simultaneous Detection of Multiple Analytes Using Copalis Technology: A Reduction to Practice. Clinical Chemistry. 44(9). 2052–2054. 15 indexed citations
14.
Hollis, Bruce W., et al.. (1996). Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clinical Chemistry. 42(4). 586–592. 117 indexed citations
15.
Hollis, B W, et al.. (1993). Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clinical Chemistry. 39(3). 529–533. 382 indexed citations
16.
Kim, Kyu‐Won, John Kamerud, David M. Livingston, & Robert J. Roon. (1988). Asparaginase II of Saccharomyces cerevisiae. Characterization of the ASP3 gene.. Journal of Biological Chemistry. 263(24). 11948–11953. 37 indexed citations
17.
Kamerud, John & Robert J. Roon. (1986). Asparaginase II of Saccharomyces cerevisiae: selection of four mutations that cause derepressed enzyme synthesis. Journal of Bacteriology. 165(1). 293–296. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simone D. Holligan Breakdown of academic impact, for papers by Rakesh R. Misra Breakdown of academic impact, for papers by Sanhong Yu Breakdown of academic impact, for papers by Tobias Weissenbacher Breakdown of academic impact, for papers by Marcel J.W. Janssen Breakdown of academic impact, for papers by Louise Hansen Breakdown of academic impact, for papers by Jérôme Guechot Breakdown of academic impact, for papers by Marco Ceroti Breakdown of academic impact, for papers by Şükrü Palanduz Breakdown of academic impact, for papers by Lieying Fan
Rankless by CCL
2026